Systemic Anti-Cancer Therapy Regimen Library
HSCT Mobilisation - filgrastim
Treatment Overview
This regimen contains a medicine where one or more biosimilars may exist. Any biosimilars used have been reviewed by the regulator (Medsafe) and relevant specialists were consulted nationally. Where regulators, in consultation with relevant specialists, have agreed that there are no clinically significant differences in either safety or effectiveness between a biosimilar and originator product, these drugs may be used interchangeably.
Cycle 1 - 14 days
filgrastim: Give filgrastim 10 microgram/kg subcutaneously ONCE daily for 4 or 5 days until stem cell harvest complete.
Cycle details
Cycle 1 - 14 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| filgrastim | 10 microgram/kg Once daily | subcutaneous injection | 1 to 5 |
filgrastim: Give filgrastim 10 microgram/kg subcutaneously ONCE daily for 4 or 5 days until stem cell harvest complete.
Full details
Cycle 1 - 14 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| filgrastim | 10 microgram/kg Once daily | subcutaneous injection |
Instructions:
Give ONCE daily until stem cell harvest complete.
|
Day: 2
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| filgrastim | 10 microgram/kg Once daily | subcutaneous injection |
Instructions:
Give ONCE daily until stem cell harvest complete.
|
Day: 3
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| filgrastim | 10 microgram/kg Once daily | subcutaneous injection |
Instructions:
Give ONCE daily until stem cell harvest complete.
|
Day: 4
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| filgrastim | 10 microgram/kg Once daily | subcutaneous injection |
Instructions:
Give ONCE daily until stem cell harvest complete.
|
Day: 5
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| filgrastim | 10 microgram/kg Once daily | subcutaneous injection |
Instructions:
Give ONCE daily until stem cell harvest complete.
|
Supportive Care Factors
No supportive care factors specified
References
Pfizer New Zealand Limited Nivestim New Zealand Datasheet 26 April 2021 https://www.medsafe.govt.nz/profs/datasheet/n/nivestiminj.pdf (Accessed 31 May 2022).
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Hematopoietic Cell Transplantation V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed [31 May 2022]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.